Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.

Melanoma research - 1 Apr 2022

Hotz Meghan J, O'Halloran Eileen A, Hill Maureen V, Hayden Kelly, Zaladonis Angela G, Deng Mengying, Olszanski Anthony J, Reddy Sanjay S, Wu Hong, Luo Biao, Farma Jeffrey M

Abstract excerpt

Tumor mutational burden (TMB) has recently been identified as a biomarker of response to immune checkpoint inhibitors in many cancers, including melanoma. Co-assessment of TMB with inflammatory markers and genetic mutations may better predict disease outcomes. The goal of this study was to evaluate the potential for TMB and somatic mutations in combination to predict the recurrence of disease in advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35213415
DOI: 10.1097/CMR.0000000000000808
PMCID: PMC9109603

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.PMID 35213415Read ↗

Gene expression and immune infiltration in melanoma patients with different mutation burden.Semantic proximity Read ↗

Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.Semantic proximity Read ↗

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.Semantic proximity Read ↗

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.Semantic proximity Read ↗

Burden of unique and low prevalence somatic mutations correlates with cancer survivalSemantic proximity Read ↗

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read ↗

Unmasking the "targetless" illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report.Semantic proximity Read ↗

Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma.Semantic proximity Read ↗

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.Semantic proximity Read ↗

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencySemantic proximity Read ↗

Serum‐based miRNAs in the prediction and detection of recurrence in melanoma patientsSemantic proximity Read ↗

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.